RxDoctor Payments Data

Andrew Behounek, NP

Family · Cedar Rapids, IANPI 1205329034

Payments from drug & device makers

$1,274in general payments, 2019–2025

Across 73 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$271
  • Boston Scientific$188
  • Pfizer$149
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$131
  • Boehringer Ingelheim$118
  • Johnson & Johnson$85
  • plus $331 from 9 others

What the payments were for

  • Food & beverage$1,14790%
  • Education$12610%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,274 in reported general payments places this provider in the 85th percentile of 1,268 family providers in Iowa.

See all family providers in Iowa

Medicare billing

Part B allowed, 2024
$6,217
Medicare patients
80
Services billed
100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrilintaTicagrelor41$22,162
EliquisApixaban31$17,657
EntrestoSacubitril/Valsartan12$10,607
JardianceEmpagliflozin19$8,723
XareltoRivaroxaban11$7,069
MyrbetriqMirabegron17$3,520
Colchicine24$1,719
ClopidogrelClopidogrel Bisulfate77$647
Bumetanide11$639
Nitroglycerin37$498
Furosemide54$348
Metoprolol Succinate51$269
Amiodarone Hcl20$263
Metoprolol Tartrate44$245
Digoxin13$214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$61$22,16241 claims
PfizerEliquis$149$17,65731 claims
NovartisEntresto$271$10,60712 claims
Boehringer IngelheimJardiance$118$8,72319 claims
Johnson & JohnsonXarelto$85$7,06911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,268 family providers in Iowa.

Other family in Cedar Rapids

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →